Biotop-report 2013
Yüklə 0,8 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- APRIL 2013
- Epig- enomics AG
- Number of Employees According to Company Size
- Contact us: Phone: +49 (0)30 / 2125-4747 E-mail: wachsen@ibb.de www.ibb.de/wachsen
5 BioTOPics 46 | September 2013 BioTOP-Report Biotechnology Deals and Product Developments A number of companies closed new cooperation agreements in 2012 and achieved major milestones in product development and approval. We present some examples of these dynamic ac- tivities:
opment programmes from a first evaluation of the colon cancer study with the active pharmaceutical ingredient MGN1703. The evaluation performed in May 2012 demonstrated the effective- ness of MGN1703 as a maintenance therapy for metastasised colon cancer impressively. MOLOGEN also plans to investigate the effect of MGN1703 in lung cancer therapy in the future. In October 2012, the company presented promising new data from its kidney cancer study with MGN1601. They showed a clear sur- vival advantage for patients who fully completed the prescribed therapy programme compared to patients who had to terminate the therapy early due to the severity of their cancer disease. Furthermore, MOLOGEN completed the preclinical phase of its MIDGE
® -based Leishmaniasis vaccine MGN1331 in June 2012 with good results.
Alacris Theranostics GmbH signs agreement with GSK to apply Alacris Mod- CellTM system in the early phase of cancer research ++++
Entry to the phar- ma market: Tönnies invests 21 million Euro, majority shareholder at Heparin specialist Pharma Action
NOXXON initiates phase IIa study on anaemia of chronical illness with anti- Hepcidin Spiegelmer ® NOX-H94 ++++ Epigenomics releases more data on the results of a direct comparative study between Epi ProColon ® and FIT JANUARY 2013 Epigenomics AG hands in fourth module at FDA completes application for approval as planned ++++
co.don ® AG applied for approval of joint cartilage product chondrosphere ® in the EU ++++ Shire discovered the Munich-based RNA specialist Ethris for itself. In cooperation the two companies want to find therapies for rare diseases FEBRUARY 2013 Epigenomics receives notice about grant of priority review status and accep- tance of the hand-in of the PMA application for Epi proColon ® from the FDA ++++ Innovation forum “Biopolymers and Bio-based Plastics” in Schwarz- heide
BIOTECON Diagnostics GmbH extends its robot segment ++++ Epigenomics AG collects 5,0 million Euros through capital increase ++++
New research col- lective INNO-TRACE develops innovative contrast agents for tumour imaging APRIL 2013 Europe's largest clinical laboratory at Campus Virchow-Klinikum: Labor Berlin inaugurates new site
Bayer HealthCare presents new incubator model for biotech start-ups in Ber- lin
Alacris Theranostics GmbH announces Illumina CSPro certificate for next gen- eration sequencing ++++
Humedics co-founder Martin Stockmann receives Von-Langenbeck Prize for development of LiMAx test Dr. Claudia Ulbrich CEO t-cell Europe GmbH Our T-cell-based therapies, unique throughout the world, can help prevent organ rejection following transplant procedures, thus significantly reducing the need for immunosuppressive drugs. With the new funds of EUR 5.5 million raised in our most recent financing round, we aim to commence clinical trials already in 2014, so that we can expeditiously move for- ward with proof-of-concept at the patient level, then proceed with negotiations to license our proprietary technology to a pharmaceutical industry partner. T-cell therapy will not com- pletely eliminate the need for immunosuppressive support. However, even if the amount of immunosuppressive drugs required can be reduced by one half, the costs of our thera- py will be quickly recovered, generating net patient savings. Just for one specific application, T reg therapy following kidney transplantation, we estimate a current market potential of more than one billion euros per year. 6 BioTOPics 46 | September 2013 BioTOP-Report Biotechnology NOXXON Pharma AG, a biopharmaceutical company and pi- oneering developer of the new active agent class spiegelmers, successfully advanced its product pipeline. Its latest candidate agent NOX-H94 is already the third spiegelmer to have reached the Phase II trial stage. This is one of four Phase IIa trials NOXXON began in 2012. The others are investigating NOX-E36 in diabetic nephropathy therapy, NOX-A12 in the therapy of chronic lym- phatic leukaemia and NOX-A12 for treatment of multiple myelo- ma. The trial for anaemia of this chronic disease is the fourth Phase II trial NOXXON launched in 2012. The German-American molecular diagnostics corporation Epig-
proColon
® in the USA and the development of its marketing strat- egy for this blood-based test for early detection of colon cancer. The next major milestone will now be the marketing launch of the product on the world‘s most important market – the USA. 0 100 200 300
400 500
600 700
800 900
1.000 1.100
1.200 1.300
1.400 1.500
1.600 1.700
1.800 1.900
2.000 2.100
2.200 2.300
2.400 2.500
2.600 '03 '04 '05 '06 '09 '10 '11 '12 '07
141 companies 1-10 employees Number of Employees According to Company Size 61 companies 11-50 employees 20 companies > 51 employees '08
'03 '04 '05 '06 '09 '10 '11 '12 '07 '08 '03 '04 '05 '06 '09 '10 '11 '12 '07 '08
Number of employees 663 1.330 2.355 In comparison to the previous year, the average number of employees per company increased by 2,7 % in the 1-10 category and 1,8 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 10%. (Source: Own survey, BioTOP database, 222 companies questioned, June 2013) Contact us: Phone: +49 (0)30 / 2125-4747 E-mail: wachsen@ibb.de www.ibb.de/wachsen Our tailored fi nancing are your key to success. Our consultants look forward to meeting you.
120501_IBBanz_biotop12_210x297.indd 1 16.04.12 10:25
Yüklə 0,8 Mb. Dostları ilə paylaş:
|